Getting it Right (and Wrong) With Leveraged Biotech ETFs

In what looks like a sequel to March 2014, high-flying biotechnology stocks and exchange traded funds are retreating amid talk of frothy valuations and a biotech bubble. At least temporarily, Friday March 20 marked the top for several of the largest biotech ETFs. That is when big-name ETFs, such as...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.